By taking advantage of an immune-phenotyping platform, LEGENDScreenTM, we measured the expression of 332 cell surface markers on B and T cells in a cross-sectional adalimumab-treated RA patient cohort with a defined ADA response. Here, ADA is linked to rheumatoid arthritis.